AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$TYRA

Tyra Biosciences, Inc.

Price · $TYRAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $TYRA in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $TYRA in the last 30 days.

Top stories · $TYRAMore →
MAY 12·Stock TitanLow

[144] Tyra Biosciences, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Tyra Biosciences, Inc. (TYRA) related to a proposed sale of securities. The filing details include information about the filer, the issuer, the class of securities being sold (Common stock), the aggregate market value, and previous sales by Daniel Bensen. The filing also mentions the relationship of the seller to the issuer and provides a detailed breakdown of the acquisition of the securities.

APR 30·Stock Titan

TYRA SEC Filings - Tyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Tyra Biosciences SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event forms, and insider trading forms. Tyra Biosciences is a clinical-stage biotechnology company focusing on precision medicines. The site offers AI-powered summaries to highlight key disclosures, clinical trial milestones, and financial commentary.

APR 24·Yahoo Finance

Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib

Guggenheim Securities has initiated coverage of Tyra Biosciences, Inc. (TYRA) with a Buy rating and a $54 price target, citing the therapeutic potential of its lead drug candidate, dabogratinib. The firm believes the drug could have significant upside if successful in various patient groups and disease areas. Furthermore, Tyra Biosciences recently appointed Habib Dable, a biopharmaceutical industry veteran, to its Board of Directors to help advance its FGFR3-targeted pipeline.

News on $TYRA

All news →